Home Mainline IPOs Mahamaya Lifesciences IPO
Orion Industries logo

Mahamaya Lifesciences IPO

Open Sme
BSE 11 November - 13 November 2025
Mahamaya Lifesciences Limited IPO is a book build issue of 70.44 Cr. The issue is a combination of fresh issue of 5329200 shares aggregating to 60.75 Cr and offer for sale of 540000 shares aggregating to 6.16 Cr. Mahamaya Lifesciences Limited IPO opened for subscription on Nov 11, 2025 and closed on Nov 13, 2025. The allotment for the this IPO was finalized on Nov 14, 2025. IPO was listed on NSE and BSE on Nov 18, 2025. Mahamaya Lifesciences Limited IPO is set issue price band at ₹108 to ₹114 per share.

Current GMP

₹0 (0.00%)

Price Band

₹ 108 – 114

Lot Size

1200

Issue Size

₹70.44 Cr

Minimum Investment

₹273600 (2400 Shares)

Listing Date

18 November 2025

Subscription

1.71x

About the Company

Mahamaya Lifesciences Limited

Incorporated: 2002
Industry: Agrochemicals and Bioproducts
Core Activities: Manufacturing, registration, and export of crop protection and soil health management products

Company Overview

Mahamaya Lifesciences Limited is a leading agrochemical company established in 2002, engaged in the manufacturing, registration, and export of high-quality crop protection products and bioproducts. The company is dedicated to enhancing crop and soil health and supporting the farming community in improving agricultural productivity and sustainability.

The company specializes in the formulation of pesticides and the supply of bulk agrochemical products to domestic agrochemical companies as well as multinational corporations (MNCs).

Mahamaya Lifesciences imports scientifically researched molecules, registers them with the Central Insecticides Board (CIB), and markets them as technical-grade and value-added formulations. These products cater to both domestic manufacturers and global MNCs.

With a strong focus on international expansion, the company has invested in global product registrations, actively operating in markets such as the Dominican Republic, Egypt, Ethiopia, Jordan, the UAE, and Turkey. The company provides high-quality products along with comprehensive data support for regulatory registrations in these countries.

Product Portfolio

1. Bulk Formulation Sales

  • Acetamiprid SP
  • Buprofezin SC
  • Emamectin Benzoate SG
  • Imidacloprid SC
  • Paraquat Dichloride SC

2. Technical Sales

  • Acetamiprid Technical (99% Min)
  • Atrazine Technical (95% Min)
  • Imidacloprid Technical (95% Min)
  • Emamectin Benzoate Technical (95% Min)

3. Branded Product Sales

Major in-house branded formulations include:

  • MAYAMRIT GR
  • MAYAMRIT SL
  • MAYAGIBB
  • UCHIT EW 370

4. Export Formulations

Key exported formulations marketed under proprietary brands:

  • Wiper – Sulphur 80% WDG
  • Lancha – Pendimethalin 50% EC
  • Tolfen – Tolfenpyrad 15% EC
  • Typic – Sulphur 80% WG

Global Presence

Mahamaya Lifesciences continues to strengthen its international footprint through product registrations and partnerships across Asia, the Middle East, and Africa, ensuring sustainable and reliable crop protection solutions for global agriculture.


Promoters

  1. Mr. Krishnamurthy Ganesan
  2. Mr. Prashant Krishnamurthy
  3. Mrs. Lalitha Krishnamurthy 


Promoters Holding

Holding Pre Issue

77.27%

Holding Post Issue

56.35%

Objects of the Issue

The Company Mahamaya Lifesciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.

  1. Purchase of Equipment for existing Formulation plant 
  2. Funding capital expenditure towards setting up of a new Technical manufacturing plant
  3. Construction of Warehouse Building and Purchase of Machinery 
  4. Funding working capital requirement of our Company 
  5. General Corporate purposes 

Address / Contact Info

Mahamaya Lifesciences Ltd.
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/

IPO Snapshot

Face Value₹10 per share
Price Band₹ 108 – 114
Lot Size1200
Issue TypeBook-building IPO
Sale TypeFresh Capital & Offer For Sale
Fresh Issue₹ 60.75 Cr
Offer for Sale₹ 6.16 Cr
Total Issue Size₹ 70.44 Cr
Listing AtBSE
IndustryTrading
SectorAgriculture
QIB Quota28.56%
BNII Quota14.28%
SNII Quota7.14%
Retail Quota50.01%

Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.

Frequently Asked Questions

Everything you need to know before applying to an IPO.

Mahamaya Lifesciences IPO is a Book-building IPO worth ₹70.44 crores. The price band is ₹108 to 114 per share. The IPO opens on Tue, Nov 11, 2025 and closes on Thu, Nov 13, 2025. It will be listed on BSE and NSE. Kfin Technologies Limited is the registrar.

The Mahamaya Lifesciences IPO opens on Tue, Nov 11, 2025 and closes on Thu, Nov 13, 2025

Mahamaya Lifesciences IPO Price Band is ₹108 to 114.

Mahamaya Lifesciences IPO lot size is 1200, and the minimum amount required for application is ₹273600.

The minimum investment for Mahamaya Lifesciences IPO is approximately ₹273600 based on the upper price band.

To apply for the Mahamaya Lifesciences IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of Thu, Nov 13, 2025. After submission, funds are blocked until the basis of allotment of Mahamaya Lifesciences IPO is finalised.

Mahamaya Lifesciences IPO issue size is ₹70.44 crores.

Mahamaya Lifesciences IPO allotment date is Sat, Jun 27, 2026.

The registrar for Mahamaya Lifesciences IPO is Kfin Technologies Limited. Investors can go to Kfin Technologies Limited website for IPO allotment status, refund processing, and other queries related to Mahamaya Lifesciences IPO through their official website or helpline.